Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients.

导出 OA

翻译打印收藏纠错

作者： Leonel,Armas-López ^[1] ; Patricia,Piña-Sánchez ^[2] ; Oscar,Arrieta ^[3] ; Enrique Guzman,de Alba ^[4] ; Blanca,Ortiz-Quintero ^[4] ; Patricio,Santillán-Doherty ^[4] ; David C,Christiani ^[5] ; Joaquín,Zúñiga ^[4] ; Federico,Ávila-Moreno ^[1]

作者单位： National University Autonomous of México (UNAM), Facultad de Estudios Superiores (FES) Iztacala, Biomedicine Research Unit (UBIMED), Lung Diseases And Cancer Epigenomics Laboratory, Mexico State, Mexico. ^[1] Instituto Mexicano del Seguro Social (IMSS), Centro Medico Nacional (CMN) Siglo XXI, Unidad de Investigación Médica en Enfermedades Oncológicas (UIMEO), Molecular Oncology Laboratory, Mexico City, Mexico. ^[2] National Cancer Institute (INCAN), Thoracic Oncology Clinic, Mexico City, Mexico. ^[3] National Institute of Respiratory Diseases (INER) "Ismael Cosío Villegas", Mexico City, Mexico. ^[4] Harvard Medical School, Harvard School of Public Health, Department of Environmental Health, Boston, Massachusetts, USA. ^[5]

关键词 epigenetics cancer drug resistance homeobox transcription factors lung cancer overall survival treatment prognosis

DOI 10.18632/oncotarget.17715

PMID 28978016

发布时间 2024-06-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交